Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vancomycin HCl,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Hm Capital
Deal Size : $30.0 million
Deal Type : Series B Financing
Details : The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 03, 2022
Lead Product(s) : Vancomycin HCl,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Hm Capital
Deal Size : $30.0 million
Deal Type : Series B Financing
Lead Product(s) : Vancomycin HCl,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VT-X7, (Vancomycin Hydrochloride), a drug/device combination product that locally delivers, via irrigation, highly targeted antibiotic therapy to the hip or knee during an accelerated seven-day interstage period of a two-stage exchange arthroplasty.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : Vancomycin HCl,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tobramycin (generic to Tobradex) Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exi...
Product Name : Tobramycin / Dexamethasone-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tobradex® Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Product Name : Tobramycin / Dexamethasone-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin,Itraconazole
Therapeutic Area : Podiatry
Study Phase : Phase I
Sponsor : Keystone Pharmacy
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin,Itraconazole
Therapeutic Area : Podiatry
Highest Development Status : Phase I
Sponsor : Keystone Pharmacy
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives Approval for Generic TobraDex®
Details : Dexamethasone & Tobramycin Ophthalmic Suspension 0.3%/0.1% is generic version of TobraDex, which is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection o...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Dexamethasone,Tobramycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin,Vancomycin HCl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonoran's lead product SBG003 (tobramycin and vancomycin hydrogel) has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food & Drug Administration (FDA) for prevention of post-abdominal surgical site infection.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 08, 2020
Lead Product(s) : Tobramycin,Vancomycin HCl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 05, 2019
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2018
Lead Product(s) : Tobramycin,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistin Sulfate,Tobramycin
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 29, 2016
Lead Product(s) : Colistin Sulfate,Tobramycin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable